Actinogen Medical Ltd. has announced the initiation of its XanaMIA phase 2b/3 clinical trial, aimed at assessing the efficacy of Xanamem, a novel oral treatment for Alzheimer's disease. This trial, now open at 20 sites across the United States, is recruiting participants diagnosed with mild to moderate Alzheimer's disease. The study examines the effects of Xanamem, which inhibits the production of cortisol in brain regions associated with memory and critical thinking, compared to a placebo over a 36-week period. Participants who complete this phase will be eligible for an open-label extension trial of Xanamem for up to 24 months, anticipated to commence in early 2026. No results from the trial have been presented yet, as participant recruitment and data collection are ongoing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。